Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

TP53 mutations in AML confer resistance to CAR T-cell therapy through exhaustion of CAR T-cells, and dysregulation of the mevalonate and Wnt pathways in AML and CAR T-cells, respectively. Targeting ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its ...

CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified ...

The study evaluates ICT01, a novel γ9δ2 T-cell activator, administered in combination with azacitidine and venetoclax (Aza-Ven) in patients with newly diagnosed acute myeloid leukemia (AML ...

SINGAPORE, May 22, 2025 /PRNewswire/ -- Azentio Software, a leading technology enabler in the BFSI space, announces the launch of its next-generation Amlock anti-money laundering (AML) platform ...

Company's AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other ...

Dale H. Cowan M.D. – Ruth Goodman Blum Professor of Cancer Research Dr. Wang’s research program focuses on defining mechanisms of oncogenesis at the molecular, regulatory and phenotypic levels and ...

ARLINGTON -- Have the Rangers signed the “Korean Ohtani”? Well, they sure hope so. The club announced on Sunday that it signed Korean two-way player Seong-Jun Kim as an international free agent. Kim, ...

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms ...

In a Monday post on Chinese microblogging site Weibo, Lei wrote that Xiaomi achieved the milestone as of April after spending 13.5 billion yuan and deploying 2,500 research-and-development (R&D ...